Innovative startups using medical data receive funding through Digital Sandbox

Six European startups in biotech, medtech and digital health receive in total €180 000 in funding to access samples and collaborate with European biobanks and quality registers. During a year the companies will participate in an innovation program, Digital Sandbox funded by EIT Health.

The digital revolution has created massive amounts of medical data that can be used for research. The program will help the startups to tap into that data to create healthcare innovations and support in helping the development of new products and services as well as starting collaborations with biobanks, sample holders and quality registers in Europe.

All companies have at least technology readiness (TRL) 3 with proof of concept demonstrated analytically. The companies are working with innovations in various areas; Acobiom, France, GlyCardial Diagnostics and Amadix, Spain, in blood biomarkers for early disease detection and personalised medicine and French BeFC that makes electricity with papers and enzymes and Radiobotics, Denmark and Healthinn:Rehand, Spain are digital health companies within AI / machine learning in need of real-world data.

“Our vision at Radiobotics is to be at the forefront of clinical research and work closely with the hospitals to fully demonstrate how our technology brings value to clinicians. Being part of the EIT Health network and Digital Sandbox we have a brilliant opportunity to evaluate our new product on real-world data, allowing us to ensure that the final product actually supports the clinicians in their work just as we have intended.” Martin Axelsen,PhD, CSO & Co-founder Radiobotics.

“We need innovative solutions that can optimise workflow, raise the quality of description of radiographs to keep up with the ever-increasing demand for diagnostic imaging. Hopefully by working with Radiobotics and new technologies we can ensure improved quality of healthcare in the treatment of patients with muscular-skeletal problems.” says Ole Graumann MD, PhD, Associate Professor, Department of Radiology, Odense University Hospital and Department of Clinical Research, University of Southern Denmark

Half of the funding is earmarked for accessing health data or biological samples and EIT Health will support the companies in establishing connections and collaboration with biobanks and registers and identify a local research partner which is crucial in order to collaborate, not only with a biobank but also with a research group to access samples from Sweden and Denmark.

“It’s our second consecutive year that we host this program and we are expanding the network to cover not only Estonia, Sweden and Denmark but also Belgium and the Netherlands. Through last year’s Digital Sandbox four companies have started collaborations with biobanks in Europe and through our networking events we have facilitated collaborations with research groups and we have advised on regulations in different countries as they vary. Estonia has for example a National Biobank which differs from Sweden and Denmark who require a local research partner”, explains Ulrika Zagai, Project Manager for Biobanks and Registers in Transition, EIT Health Scandinavia

Digital Sandbox Awarded Companies 2020

Acobiom – France

Acobiom is a biotechnology company specialised in the discovery of new biomarkers and in the development of innovative diagnostics. Expertise and knowledge in genomics, statistics, and machine learning.

The goal of the funded project is to use biomarkers for diagnosing and personalised treatment of pancreatic cancer. To succeed, clinical data and real-world data from different biobanks will be evaluated.

Area: Medtech

Contact: David Piquemal

Email: piquemal@acobiom.com

Website: http://www.acobiom.com/en/

Twitter: https://twitter.com/acobiom_biotech

LinkedIn: https://www.linkedin.com/company/acobiom/

Amadix Advanced Markers Discovery – Spain

Amadix is a biotechnology company developing innovative diagnostic tools in oncology to improve the diagnosis of different types of cancer through a non-invasive test. Amadix develops and commercialises diagnostic tools that address unmet medical needs. Amadix has a pipeline of innovative tests in development, for early diagnosis in colon, lung, and pancreatic cancer.

The goal of the funded project is to develop a test for early detection of colon cancer. In order to succeed Amadix needs access to health data from patients that have undergone a colonoscopy.

Area: Biotech

Contact: Lucía Reinoso

Email: lreinoso@amadix.com

Website: amadix.com

Twitter: https://twitter.com/AmadixDx

LinkedIn: https://www.linkedin.com/company/amadix/

BeFC Bioenzymatic Fuel Cells – France

BeFC makes electricity from papers and enzymes. The goal is to use eco-friendly paper based Bioenzymatic Fuel Cells (BeFC) in medical disposables like pregnancy tests to eliminate the environmental impact.

Area: Biotech

Contact: Jules Hammond and Marie Berthuel

Email: jules.hammond@befc.fr, marie.berthuel@befc.fr

Website: befc.global/

Twitter: https://twitter.com/BeFC_fr

LinkedIn: https://www.linkedin.com/company/bioenzymaticfuelcells/

GlyCardial Diagnostics – Spain

Early diagnosis of cardiac ischemic events to reduce the impact of the disease on patients’ life. In ischemic events time is gold, we want to provide cardiologists with a tool so that they can act before it is too late.

In the funded project GlyCardial is focused on the development of a novel diagnostic test for the early detection cardiac events. To succeed, GlyCardial wants to use existing health data and biobank samples, more specific serum samples and anonymised clinical history data of patients within cardiology.

Area: Medtech

Contact: Judit Cubedo

Email: jcubedo@glycardial.com

Website: glycardial.com

Twitter: https://twitter.com/GlyCardial

LinkedIn: https://www.linkedin.com/company/glycardialdiagnostics/

Healthinn:Rehand – Spain

Healthinn:Rehand Rehabilitation solutions to solve current health problems and thereby improving the quality of life of patients. The first tablet solution for the rehabilitation of hand, wrist, and fingers. The devices also support decisions taken by healthcare professionals.

To empower their product demographic and clinical data related to the recovery of the injuries and surgical interventions in hand, wrist, and fingers, from thousands of patients will be used. Such data is accessible in Scandinavian quality registers.

Area: Digital health

Contact: Jesús Blanquero Villar

Email: jesusblanquero@rehand.net

Website: rehand.net

Twitter: https://twitter.com/HealthinnTech

LinkedIn: https://www.linkedin.com/showcase/rehand/

Radiobotics – Denmark

Radiobotics is developing algorithms for automatic analysis and description of routine medical x-ray images at hospitals, within musculoskeletal radiology.

In the funded project Radiobotics is developing a product for automatic analysis of radiographs of the hip. The developed machine learning model needs exposure to real-world data in order to ensure generalisability. This can be achieved by access to retrospectively collected digital radiographs of the pelvis and will allow for product validation. Such a data sample is for example accessible via a research sample collection in Denmark.

Area: Digital health

Contact: Martin Christian Axelsen and Stine Mølgaard Sørensen

Email: martin@radiobotics.com, stine@radiobotics.com

Website: radiobotics.com

Twitter: https://twitter.com/radiobotics

LinkedIn: https://www.linkedin.com/company/radiobotics/

About Radiobotics 

Radiobotics is an award-winning health tech startup with a vision to automate the analysis and description of routine medical x-ray images at hospitals, with a focus on musculoskeletal radiology (MSk). Based on advanced computer vision and state-of-the-art machine learning methods, Radiobotics’ algorithms generate fully automated text reports with objective findings and conclusion, including visual overlays, to enhance consistency and make it faster and easier to make readings on routine medical x-ray images.

Radiobotics develops scientifically and clinically validated algorithms based on deep clinical understanding. The technology is designed and developed in close collaboration with clinicians to address their needs and requirements from the start. www.radiobotics.com

 

About EIT Health Scandinavia 

EIT Health is a Knowledge and Innovation Community (KIC) established by the EU body European Institute for Innovation & Technology (EIT). EIT Health is a collaboration between more than 150 Partners within pharma, medtech, healthcare and healthcare funders, research institutions, and universities. Backed by the European Union, EIT Health is Europe’s largest life science collaboration organisation, and one of the largest life science initiatives world-wide. EIT Health is active across three fields: business creation, education, and multidisciplinary healthcare innovation initiatives.

EIT Health has Partners and programmes in 17 countries. The other Co-Location Centres are present in Barcelona, Paris, London, Rotterdam, Heidelberg-Mannheim and Budapest. The headquarter of EIT Health is located in Munich. EIT Health Scandinavia covers Sweden, Denmark and Estonia, and the main office is located in Stockholm.

Core Partners: Karolinska Institute (KI),Technical University of Denmark (DTU),   Royal Institute of Technology (KTH), Region Skåne, Region Stockholm, RISE, Thermo Fischer Scientific, University of Copenhagen (UCPH),University of Tartu and Uppsala University.

Associate Partners: AstraZeneca, City of Uppsala, Copenhagen Business School (CBS), , Novo Nordisk, Region Uppsala and The Capital Region of Copenhagen

Linked/Affiliated Parties: Entreprenörstiftelsen Drivhuset, Karolinska Institute Innovations AB, Karolinska University Hospital, Life Technologies Corporation, RISE Acreo AB, RISE Interactive Institute AB, RISE SICS AB. Smile Incubator, Stockholm Innovation & Growth AB, Tartu University Hospital, Uppsala Innovation Centre AB